- Home
- AVTX vs AVIR Comparison
AVTX vs AVIR Comparison
Compare AVTX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- AVIR
- Stock Information
- Founded
- AVTX 2011
- AVIR 2012
- Country
- AVTX United States
- AVIR United States
- Employees
- AVTX N/A
- AVIR N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AVTX Health Care
- AVIR Health Care
- Exchange
- AVTX Nasdaq
- AVIR Nasdaq
- Market Cap
- AVTX 248.3M
- AVIR 239.1M
- IPO Year
- AVTX 2015
- AVIR 2020
- Fundamental
- Price
- AVTX $15.14
- AVIR $2.97
- Analyst Decision
- AVTX Strong Buy
- AVIR Hold
- Analyst Count
- AVTX 9
- AVIR 1
- Target Price
- AVTX $30.14
- AVIR $6.00
- AVG Volume (30 Days)
- AVTX 412.1K
- AVIR 433.0K
- Earning Date
- AVTX 11-06-2025
- AVIR 11-12-2025
- Dividend Yield
- AVTX N/A
- AVIR N/A
- EPS Growth
- AVTX N/A
- AVIR N/A
- EPS
- AVTX N/A
- AVIR N/A
- Revenue
- AVTX $192,000.00
- AVIR N/A
- Revenue This Year
- AVTX N/A
- AVIR N/A
- Revenue Next Year
- AVTX N/A
- AVIR N/A
- P/E Ratio
- AVTX N/A
- AVIR N/A
- Revenue Growth
- AVTX N/A
- AVIR N/A
- 52 Week Low
- AVTX $3.39
- AVIR $2.46
- 52 Week High
- AVTX $19.41
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- AVTX 48.12
- AVIR 37.69
- Support Level
- AVTX $14.16
- AVIR $2.87
- Resistance Level
- AVTX $16.03
- AVIR $3.50
- Average True Range (ATR)
- AVTX 1.27
- AVIR 0.12
- MACD
- AVTX -0.42
- AVIR -0.02
- Stochastic Oscillator
- AVTX 23.40
- AVIR 13.49
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).